Skip to main content
. 2022 Aug 24;14(9):1861. doi: 10.3390/v14091861

Figure 1.

Figure 1

RBD-specific IgG levels and ACE2 inhibition for SARS-CoV-2 WT and four VoCs in symptomatic and paucisymptomatic subjects. RBD-specific IgG binding ((a,c) (antibody level, fold negative cut-off AU)) and ACE2 inhibition ((b,d) (normalized percent inhibition)) against the WT, Alpha, Beta, Gamma, and Omicron variants was measured in subjects with severe symptoms (a,b) and paucisymptomatic subjects (c,d). A Freidman test with Dunn post-hoc test was performed between all possible combinations (* p = 0.05, ** p = 0.01, *** p = 0.001 and **** p = 0.0001).